Medtronic (MDT) Up 5.6% Since Last Earnings Report: Can It Continue?

It has been about a month since the last earnings report for Medtronic (MDT). Shares have added about 5.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Medtronic due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns out, fresh estimates have trended downward during the past month.VGM ScoresCurrently, Medtronic has an average Growth Score of C, however its Momentum Score is doing a bit better with a B. Charting a somewhat similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Medtronic has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerMedtronic belongs to the Zacks Medical - Products industry. Another stock from the same industry, Haemonetics (HAE), has gained 2.5% over the past month. More than a month has passed since the company reported results for the quarter ended December 2024.Haemonetics reported revenues of $348.54 million in the last reported quarter, representing a year-over-year change of +3.7%. EPS of $1.19 for the same period compares with $1.04 a year ago.Haemonetics is expected to post earnings of $1.22 per share for the current quarter, representing a year-over-year change of +35.6%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.3%.The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Haemonetics. Also, the stock has a VGM Score of F.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT): Free Stock Analysis Report Haemonetics Corporation (HAE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks